Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism

Abstract

Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.

What is claimed is:  
     
         1 . A composition comprising a monoamine oxidase B (MAOB) inhibitor and an aldehyde dehydrogenase (ALDH) inhibitor.  
     
     
         2 . The composition according to  claim 1 , wherein the aldehyde dehydrogenase inhibitor inhibits the activity of aldehyde dehydrogenase-I.  
     
     
         3 . The composition according to claim l, wherein the aldehyde dehydrogenase inhibitor is selected from the group consisting: of disulfiram, coprine, cyanamide, 1-aminocyclopropanol, daidzin, cephalosporin, antidiabetic sulfonyl urea, metronidazole, and metabolites or analogs thereof that exhibit aldehyde dehydrogenase-inhibiting activity.  
     
     
         4 . The composition according to  claim 1 , wherein the aldehyde dehydrogenase is disulfiram or a metabolite or analog thereof that exhibits aldehyde dehydrogenase-inhibiting activity.  
     
     
         5 . The composition according to  claim 1 , wherein the composition comprises an amount of disulfiram selected from the group consisting of: about 500 mg, about 250 mg, about 125 mg and about 60 mg of disulfiram.  
     
     
         6 . The composition according to  claim 1 , wherein the monoamine oxidase B inhibitor is selected from the group consisting of: selegiline, pargyline, desmethylselegiline, rasagiline, 3-N-phenylacetylamino-2,5-piperidinedione and caroxyazone.  
     
     
         7 . The composition according to of  claim 1 , wherein the monoamine oxidase inhibitor B is selegiline.  
     
     
         8 . The composition according to  claim 7 , wherein the composition comprises an amount of selegiline selected from the group consisting of: about 15 mg or less, about 10 mg or less, about 5 mg or less, about 2.5 or less and about 1 or less mg of selegiline.  
     
     
         9 . The composition according to  claim 1 , wherein the monoamine oxidase inhibitor B is selegiline and the aldehyde dehydrogenase inhibitor is disulfiram.  
     
     
         10 . A method for preventing, treating or reducing alcoholism in a patient in need for treatment thereof comprising the step of administering a therapeutically effective amount of a composition comprising a monoamine oxidase B inhibitor and an aldehyde dehydrogenase inhibitor.  
     
     
         11 . The method of  claim 10  wherein the aldehyde dehydrogenase inhibitor inhibits aldehyde dehydrogenase-I.  
     
     
         12 . The method according to  claim 10 , wherein the aldehyde dehydrogenase inhibitor is selected from the group consisting of: disulfiram, coprine, cyanamide, 1-aminocyclopropanol, daidzin, cephalosporin, antidiabetic sulfonyl urea, metronidazole, and metabolites or analogs thereof exhibiting aldehyde dehydrogenase-inhibiting activity.  
     
     
         13 . The method according to  claim 10 , wherein the aldehyde dehydrogenase inhibitor is disulfiram, or a metabolite or analog thereof that exhibits aldehyde-dehydrogenase-inhibiting activity.  
     
     
         14 . The method according to  claim 13 , wherein the amount of disulfiram administered to said patient per day is selected from the group consisting of about 500 mg, about 250 mg, about 125 mg and about 60 mg.  
     
     
         15 . The method according to  claim 10 , wherein the monoamine oxidase B inhibitor is selected from the group consisting of: selegiline, pargyline, desmethylselegiline, rasagiline, 3-N-phenylacetylamino-2,5-piperidinedione and caroxyazone.  
     
     
         16 . The method according to  claim 10 , wherein the monoamine oxidase B inhibitor is selegiline.  
     
     
         17 . The method according to  claim 16 , wherein the amount of selegiline administered to said patient per day is selected from the group consisting of: 15 mg or less, 10 mg or less, 5 mg or less, 2.5 mg or less, and 1 mg or less of selegiline.  
     
     
         18 . The method according to  claim 10 , wherein the monoamine oxidase inhibitor B is selegiline and the aldehyde dehydrogenase inhibitor is disulfiram.  
     
     
         19 . The method according to  claim 10 , wherein the composition is administered orally, parentally or transdermally.  
     
     
         20 . The method according to  claim 19 , wherein the composition is administered as a capsule, a tablet or a transdermal patch.  
     
     
         21 . The method according to  claim 10 , wherein the patient is a human.  
     
     
         22 . A method of increasing patient compliance with a therapeutic regimen comprising self-administration of an aldehyde dehydrogenase inhibitor, comprising the step of administering to the patient a therapeutically effective amount of a monoamine oxidase B inhibitor.  
     
     
         23 . The method according to  claim 22 , wherein the patient suffers with alcoholism.  
     
     
         24 . The method according to  claim 22 , wherein the aldehyde dehydrogenase inhibitor inhibits aldehyde dehydrogenase-I.  
     
     
         25 . The method according to  claim 22 , wherein the aldehyde dehydrogenase inhibitor is selected from the group consisting of: disulfiram, coprine, cyanamide, 1-aminocyclopropanol, daidzin, cephalosporin, antidiabetic sulfonyl urea, metronidazole, and metabolites or analogs thereof exhibiting aldehyde dehydrogenase-inhibiting activity.  
     
     
         26 . The method according to  claim 22 , wherein the aldehyde dehydrogenase inhibitor is disulfiram, or a metabolite or analog thereof that exhibits aldehyde-dehydrogenase-inhibiting activity.  
     
     
         27 . The method according to  claim 26 , wherein the amount of disulfiram administered to said patient per day is selected from the group consisting of about 500 mg, about 250 mg, about 125 mg and about 60 mg.  
     
     
         28 . The method according to  claim 22 , wherein the monoamine oxidase B inhibitor is selected from the group consisting of: selegiline, pargyline, desmethylselegiline, rasagiline, 3-N-phenylacetylamino-2,5-piperidinedione and caroxyazone.  
     
     
         29 . The method according to  claim 22 , wherein the monoamine oxidase B inhibitor is selegiline.  
     
     
         30 . The method according to  claim 29 , wherein the amount of selegiline administered to said patient per day is selected from the group consisting of: 15 mg or less, 10 mg or less, 5 mg or less, 2.5 mg or less, and 1 mg or less of selegiline.  
     
     
         31 . The method according to  claim 22 , wherein the monoamine oxidase inhibitor B is selegiline and the aldehyde dehydrogenase inhibitor is disulfiram.  
     
     
         32 . The method according to  claim 31 , wherein the composition is administered orally, parentally or transdermally.  
     
     
         33 . The method according to  claim 32 , wherein the composition is administered as a capsule, a tablet or a transdermal patch.  
     
     
         34 . The method according to  claim 22 , wherein the patient is a human.